

11-28-01

Please type a plus sign (+) inside this box → +


SUBSTITUTE for PTO/SB/05 (08/00) Utility Patent Application Transmittal
 Approved for use through 10/31/2002 OMB 0651-0032
 U S Patent and Trademark Office. U S DEPARTMENT OF COMMERCE



UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.		20385YDA
First Inventor or Application Identifier		Bakshi et al.
Title	SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS	
Express Mail Label No.		EL523911012US

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents

1. Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. Specification [Total Pages **101**]
3. Drawing(s) (35 USC 113) [Total Sheets]
[Total Pages]
4. Oath or Declaration
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 14 completed)
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
5. Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

6. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. Computer Readable Form
 - b. Paper Copy (identical to computer copy)
 - c. Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. Assignment papers (cover sheet & document(s))
8. 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)
9. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
10. Preliminary Amendment
11. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
12. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
13. Other: _____

14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

 Continuation Divisional Continuation-in-part (CIP) of prior application No. **09 / 585,111**

Prior application information: Examiner Seaman, D. Group/Art Unit: 1625

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

15. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label	Customer No. 000210 (Insert Customer No. or Attach bar code here)	
---	---	--

NAME	Melvin Winokur			
ADDRESS	Merck & Co., Inc , P O. Box 2000 - Patent Dept., RY60-30			
CITY	Rahway	STATE	NJ	ZIP CODE
COUNTRY	USA	TELEPHONE	732-594- 7234	FAX
				732-594-4720

Name	Melvin Winokur	Registration No. (Attorney/Agent)	32,763
Signature			Date 11/21/2001

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT November 21, 2001

EXPRESS MAIL NO. EL523911012US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, BOX PATENT APPLICATION, WASHINGTON, D.C. 20231.

MAILED BY DATE 11/21/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231

Prior Application:

Examiner	Seaman, D.
Art Unit	1625

Sir: This is a request for filing a Continuation Divisional

application, under 37 C.F.R. 1.53(b), of pending application Serial No. 09/585,111 filed on

June 1, 2000 of Bakshi et al.
(DATE) (INVENTOR)

for SUBSTITUTED PIPERIDINES AS MELANOCORTIN-4 RECEPTOR AGONISTS
(TITLE OF INVENTION)

1. The enclosed comprises a copy of prior application Serial No. 09/585,111, as filed on

June 1, 2000. The entire disclosure of this prior application is hereby incorporated by reference.

2. The filing fee is calculated below:

CLAIMS AS FILED IN THE PRIOR APPLICATION, LESS ANY CLAIMS CANCELED BY AMENDMENT BELOW

FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
Total Claims	38	-	20	18 x \$18 = \$324
Independent Claims	10	-	3	7 x \$84 = \$588
*Multiple Dependent Claims				\$280
Basic Fee (minimum amount required)				\$740
* Add this fee if application contains any multiple dependent claims, regardless of number.				\$1,652 Total Fee

3. The Assistant Commissioner is hereby authorized to charge any fees which may be required or to credit any overpayment to Account No. 13-2755.

4. Amend the specification by inserting before the first line the sentence:
-- This is a continuation, division of application Serial No. _____, filed _____.

5. Cancel in this application original claims: _____.

6. Preliminary amendment enclosed.

7. Information Disclosure Statement/PTO-1449 enclosed.

8a. Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.

8b. New formal drawings are enclosed.

9a. Priority of application Serial No. _____, filed _____, in _____ is claimed under 35 U.S.C. 119.
(COUNTRY)

9b. The certified copy of the priority application has been filed in prior application Serial No. _____, filed _____.

10. The prior application is assigned to Merck & Co., Inc. _____.

11. The undersigned attorney or agent has:

- Power in the prior application as originally filed.
- Associate power, copy enclosed.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT November 21, 2001

EXPRESS MAIL NO. EL523911012US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231

MAILED BY G.B. Crowley

DATE 11/21/01

Respectfully,

By: Melvin Winokur

Attorney _____ for Applicant(s)

Registration No. 32,763

Telephone: (732) 594-7234

Address: Merck & Co., Inc.
Patent Department
P.O. Box 2000 - RY60-30
Rahway, N.J. 07065-0907

Date: November 21, 2001

IN DUPLICATE

Enclosure